Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9520504 | 0.69 | SMN1; SMN2 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14046214 | 0.64 | TP53 (0.34) | TP53THRBSMN1; SMN2 | |
| SCHEMBL20229727 | 0.63 | SMN1; SMN2 (0.33) | ALDH1A1HPGDTP53THRBSMN1; SMN2 | |
| SCHEMBL9215127 | 0.61 | MAPT (0.36) | ALDH1A1HPGDTP53SMN1; SMN2 | |
| SCHEMBL12463956 | 0.59 | MAPK8 (0.33) | — | |
| SCHEMBL4434358 | 0.58 | GABRA1 (0.32) | — | |
| SCHEMBL45854 | 0.57 | — | — | |
| SCHEMBL12672770 | 0.56 | MAPK8 (0.31) | — | |
| SCHEMBL21373272 | 0.55 | MAPK8 (0.33) | ALDH1A1 | |
| SCHEMBL10663989 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| EP-4249472-A2 | METHODS FOR MODULATING RNA SPLICING | PTC Therapeutics, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | US | disclosed |
| EP-3644996-B1 | METHODS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11702646-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-3310169-B1 | METHODS FOR MODULATING RNA SPLICING | PTC THERAPEUTICS INC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-11602567-B2 | Methods for modulating RNA splicing | PTC THERAPEUTICS, INC. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3082820-B1 | METHODS FOR MODULATING THE AMOUNT OF RNA TRANSCRIPTS | PTC THERAPEUTICS INC (US) | 2022-07-20 | — | — | EP | disclosed |
| US-8895599-B2 | Lipoprotein lipase-activating compositions comprising benzene derivates | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2014-11-25 | — | — | US | disclosed |
| EP-2797592-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| WO-2013142236-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-26 | — | — | WO | disclosed |
| WO-2013130689-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| WO-2013119916-A2 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013112788-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2013101974-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| EP-2280706-B1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | ALDH1A1 1088/4885HPGD 1375/4885TP53 4877/4885 |
| US-20130296342-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATES | LPL, LIPC, LIPE | ALDH1A1 332/4885HPGD 1821/4885TP53 2205/4885 |
| US-20230272367-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, HNRNPM | ALDH1A1 3830/4885HPGD 4335/4885TP53 4515/4885 |
| US-20110065728-A1 | LIPOPROTEIN LIPASE-ACTIVATING COMPOSITIONS COMPRISING BENZENE DERIVATIVES | LPL, LIPC, LIPE | ALDH1A1 419/4885HPGD 1354/4885TP53 1982/4885 |
| US-11702646-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, HNRNPM | ALDH1A1 3830/4885HPGD 4335/4885TP53 4515/4885 |
| US-11602567-B2 | Methods for modulating RNA splicing | RBM17, SNRPE, RBM3 | ALDH1A1 3799/4885HPGD 4349/4885TP53 4236/4885 |
| US-20230310651-A1 | METHODS FOR MODULATING RNA SPLICING | RBM17, SNRPE, RBM3 | ALDH1A1 3799/4885HPGD 4349/4885TP53 4236/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | ALDH1A1 1651/4885HPGD 2194/4885TP53 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.